Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance the GAUSS-3 randomized clinical trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00060156" target="_blank" >RIV/00023001:_____/16:00060156 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10326135 RIV/00064165:_____/16:10326135
Result on the web
<a href="http://jamanetwork.com/journals/jama/fullarticle/2511043" target="_blank" >http://jamanetwork.com/journals/jama/fullarticle/2511043</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1001/jama.2016.3608" target="_blank" >10.1001/jama.2016.3608</a>

Result language
angličtina
Original language name
Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance the GAUSS-3 randomized clinical trial
Original language description
Muscle-related statin intolerance is reported by 5% to 20% of patients. To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab. Among patients with statin intolerance related to muscle-related adverse effects, the use of evolocumab compared with ezetimibe resulted in a significantly greater reduction in LDL-C levels after 24 weeks. Further studies are needed to assess long-term efficacy and safety.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)